Muenchner Studienzentrum
- Address
- lock Available on a paid plan
Neoplasms
At Muenchner Studienzentrum, clinical research in neoplasms focuses on hepatocellular carcinoma and the role of adjuvant treatment after local or surgical control of disease. These studies are designed to assess whether a new therapy can help improve long-term cancer outcomes and reduce the chance of recurrence.
- Evaluating overall survival in hepatocellular carcinoma
- Comparing recurrence-free survival after cancer treatment
- Studying the benefit of adjuvant therapy in preventing disease return
This work supports better treatment strategies for patients with liver cancer, with a clear focus on measuring effectiveness and long-term benefit.
Immune System Diseases
The site also conducts research in immune system diseases, with a strong emphasis on immunoglobulin A nephropathy and kidney protection. The goal is to determine whether a new treatment can reduce proteinuria and help preserve kidney function in adults living with this condition.
- Assessing treatment impact in immunoglobulin A nephropathy
- Measuring changes in proteinuria as a sign of disease control
- Evaluating preservation of eGFR and kidney health
Research in this area aims to improve symptom control and slow disease progression through more effective therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Muenchner Studienzentrum
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | May 2019 | Jul 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 1 | Unknown | 2019-05-20 | 2019-05-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.